Third Generation EGFR Inhibitors: Overcoming EGFR Resistance and Toxicity Problems reviews current issues relating to the design of reversible and irreversible third generation EGFR inhibitors, highlighting the types of mutation responsible for resistance, and providing different chemical starting points for researchers to optimize and develop in designing the next generation of drugs. Beginning with an introduction to EGFR inhibitors and a review of inhibitors currently approved or in clinical trials, the book goes on to discuss current approaches in the development of both covalent irreversible and covalent reversible EGFR Inhibitors. In addition, mechanisms of resistance to third generation inhibitors, and discovery of fourth generation allosteric C797S inhibitors are explored before a discussion of potential future trends.
This comprehensive coverage of the design and development of improved analogues to overcome the problems of resistance and toxicity associated with third generation EGFR inhibitors makes Third Generation EGFR Inhibitors a crucial resource for medicinal chemists, drug developers, and researchers investigating cancer therapeutics.
Les informations fournies dans la section « Synopsis » peuvent faire référence à une autre édition de ce titre.
Harun Patel is an Associate Professor in the Division of Computer Aided Drug Design, at the R. C. Patel Institute of Pharmaceutical Education and Research's Dept. of Pharmaceutical Chemistry. In addition to being the recipient of multiple awards, Dr Patel has over 70 publications in reputed peer reviewed international journals (which have achieved over 600 citations), three international books, and two patents to his name. His key research interests involve QSAR, docking studies, virtual screening, and synthesis of novel anticancer, anti-tubercular and antiepileptic drugs.
Rahul Pawara is an Associate Professor in the Division of Computer Aided Drug Design, at the R. C. Patel Institute of Pharmaceutical Education and Research's Dept. of Pharmaceutical Chemistry, which he joined following two years of work as a Field Officer in an ICMR-funded project studying Tuberculosis in tribal areas. He has five international publications in peer reviewed journals, and his main research interest is the design and synthesis of novel anti-cancer agents.
Les informations fournies dans la section « A propos du livre » peuvent faire référence à une autre édition de ce titre.
Vendeur : Brook Bookstore On Demand, Napoli, NA, Italie
Etat : new. Questo è un articolo print on demand. N° de réf. du vendeur 6260c856c823f6978abd00d4cca4b4ba
Quantité disponible : Plus de 20 disponibles
Vendeur : GreatBookPrices, Columbia, MD, Etats-Unis
Etat : New. N° de réf. du vendeur 34646715-n
Quantité disponible : 1 disponible(s)
Vendeur : BuchWeltWeit Ludwig Meier e.K., Bergisch Gladbach, Allemagne
Taschenbuch. Etat : Neu. This item is printed on demand - it takes 3-4 days longer - Neuware -Third Generation EGFR Inhibitors: Overcoming EGFR Resistance and Toxicity Problems reviews current issues relating to the design of reversible and irreversible third generation EGFR inhibitors, highlighting the types of mutation responsible for resistance, and providing different chemical starting points for researchers to optimize and develop in designing the next generation of drugs. Beginning with an introduction to EGFR inhibitors and a review of inhibitors currently approved or in clinical trials, the book goes on to discuss current approaches in the development of both covalent irreversible and covalent reversible EGFR Inhibitors. In addition, mechanisms of resistance to third generation inhibitors, and discovery of fourth generation allosteric C797S inhibitors are explored before a discussion of potential future trends. This comprehensive coverage of the design and development of improved analogues to overcome the problems of resistance and toxicity associated with third generation EGFR inhibitors makes Third Generation EGFR Inhibitors a crucial resource for medicinal chemists, drug developers, and researchers investigating cancer therapeutics. Englisch. N° de réf. du vendeur 9780081026618
Quantité disponible : 2 disponible(s)
Vendeur : GreatBookPrices, Columbia, MD, Etats-Unis
Etat : As New. Unread book in perfect condition. N° de réf. du vendeur 34646715
Quantité disponible : 1 disponible(s)
Vendeur : Majestic Books, Hounslow, Royaume-Uni
Etat : New. pp. 290. N° de réf. du vendeur 370359922
Quantité disponible : 3 disponible(s)
Vendeur : Revaluation Books, Exeter, Royaume-Uni
Paperback. Etat : Brand New. 290 pages. 9.00x6.00x0.55 inches. In Stock. This item is printed on demand. N° de réf. du vendeur __0081026617
Quantité disponible : 2 disponible(s)
Vendeur : Books Puddle, New York, NY, Etats-Unis
Etat : New. pp. 290. N° de réf. du vendeur 26375685549
Quantité disponible : 3 disponible(s)
Vendeur : Biblios, Frankfurt am main, HESSE, Allemagne
Etat : New. pp. 290. N° de réf. du vendeur 18375685543
Quantité disponible : 3 disponible(s)
Vendeur : preigu, Osnabrück, Allemagne
Taschenbuch. Etat : Neu. Third Generation EGFR Inhibitors | Overcoming EGFR Resistance and Toxicity Problems | Harun M. Patel (u. a.) | Taschenbuch | Einband - fest (Hardcover) | Englisch | 2018 | Elsevier | EAN 9780081026618 | Verantwortliche Person für die EU: Zeitfracht Medien GmbH, Ferdinand-Jühlke-Str. 7, 99095 Erfurt, produktsicherheit[at]zeitfracht[dot]de | Anbieter: preigu. N° de réf. du vendeur 126704378
Quantité disponible : 5 disponible(s)
Vendeur : GreatBookPricesUK, Woodford Green, Royaume-Uni
Etat : New. N° de réf. du vendeur 34646715-n
Quantité disponible : Plus de 20 disponibles